Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

24 May 2017, Bangkok – This April and May, the targeted malaria elimination (TME) study in Laos’ final prevalence survey evaluated new tools to detect asymptomatic malaria. These included new rapid diagnostic tests (RDTs) that may be similar in sensitivity to a PCR performed on dried blood spots and reading machines that fire a laser at RDTs and use a thermal camera to detect faint positive results that would be beyond the range of the human eye.

Various researchers

Developed by Intellectual Ventures Laboratory with support from the Bill and Melinda Gates Foundation via Global Good, both are potential new malaria elimination tools as they could identify rapidly the asymptomatic reservoir of falciparum infections. Results are expected late summer 2017 comparing the new RDTs and readers to a gold standard method of malaria detection, the quantitative PCR results from Mallika Imwong’s molecular laboratory at MORU.

A team led by LOMWRU scientists Mayfong Mayxay and Koukeo Phommasone (bottom right), Tiengkham Pongvongsa (bottom centre), head of malaria control in Savannakhet Province, and WWARN’s Mehul Dhorda and MORU’s Lorenz von Seidlein and Tom Peto hosted Kevin Nichols and Stephen Burkhor (top left) of Intellectual Ventures Laboratory (IVL) to field test the tools.

Funded by the Bill and Melinda Gates Foundation, the MORU TME project seeks to accelerate malaria elimination by providing mass drug administrations (MDA) to communities that have relatively high P. falciparum prevalence, access to village health malaria workers and where every household has one or more long lasting insecticide treated bed nets. The TME project operates in four Greater Mekong Subregion countries: Myanmar, Cambodia, Laos and Viet Nam.

In Laos, the TME project focuses on rural villages in Savannakhet province, which has the third highest malaria incidence in Lao PDR. A survey conducted in 18 rural villages in Savannakhet in 2015 using uPCR detected Plasmodium infections in 175 of 888 samples (20%). Most villages in Savannakhet are relatively accessible and malaria elimination has a high priority for the local government. LOMWRU’s Dr Mayfong Mayxay is the principal investigator (PI) for the Lao PDR study, while Dr Koukeo Phommasone is the field site PI.

Similar stories

RECOVERY trial closes recruitment to convalescent plasma treatment for patients hospitalised with COVID-19

@Oxford Research

Convalescent plasma has been widely used as a treatment for COVID-19 but to date there has been no convincing evidence of the effect of convalescent plasma on clinical outcomes in patients admitted to hospital with COVID-19. Recruitment to the convalescent plasma arm of the RECOVERY trial has now closed. The preliminary analysis based on 1873 reported deaths among 10,406 randomised patients shows no significant difference in the primary endpoint of 28-day mortality. Recruitment to all other treatment arms – tocilizumab, aspirin, colchicine, and Regeneron’s antibody cocktail – continues as planned.

Check-list recommended to improve reporting of microscopy methods and results in malaria studies

@Oxford MORU Publication Research

A study to explore the variations of how microscopy methods are reported in published malaria studies has recommended standardised procedures should be implemented for methodological consistency and comparability of clinical trial outcomes.

Receiving and responding to community feedback during health system crises in Kenya

KWTRP Publication Research

The responsiveness of a health system is one of its goals, alongside fairness in financing and outcomes. Listening and responding to the public can make a health system stronger and fairer. However, responsiveness is likely to be undermined, especially for vulnerable and marginal populations, in periods of crises such as disease outbreaks. In the current COVID-19 crisis, there has been more focus on health system control interventions, with minimal consideration of community views. KWTRP colleagues in Kenya consider community engagement and citizens feedback channels, concerns raised by the public and how they were handled, and highlight lessons learned.

RECOVERY trial finds no benefit from azithromycin in patients hospitalised with COVID-19

@Oxford Research

Established in March 2020, the RECOVERY trial tests a range of potential treatments for COVID-19, including azithromycin, a widely used antibiotic that also reduces inflammation. The azithromycin arm of the trial was established to determine whether or not the drug has a meaningful benefit among patients hospitalised with COVID-19. A preliminary analysis shows no significant difference in the primary endpoint of 28-day mortality; there was also no evidence of beneficial effects on the risk of progression to mechanical ventilation or length of hospital stay.

The COVID-19 vaccine: do we know enough to end the pandemic?

@Oxford MORU

Blog by Rima Shretta. Preliminary efficacy results from three vaccine candidates currently in Phase 3 trials have shown an efficacy of more than 90% against the development of symptomatic COVID-19. While these results are promising, all vaccines are in relatively early stages of testing. A comprehensive and transparent roadmap is urgently needed, to determine how limited doses of the first vaccines to be licensed will be distributed, together with which groups will initially be prioritized.

New study on the risk of Plasmodium vivax parasitaemia after Plasmodium falciparum malaria

@Oxford MORU Publication Research

A new study quantifying the high risk of Plasmodium vivax parasitaemia after treatment of Plasmodium falciparum malaria aims to identify populations in which a policy of universal radical cure, combining artemisinin-based combination therapy with a hypnozoitocidal antimalarial drug, would be most beneficial.